Abstract | OBJECTIVES: METHODS: We reviewed complete electronic records for all patients who, during a 3 year period, had received ≥6 days of treatment with trimethoprim/sulfamethoxazole and for whom a baseline and follow-up determination of serum creatinine and blood urea nitrogen (BUN) were available. RESULTS: CONCLUSIONS: In a middle-aged male inpatient population treated for a minimum of 6 days, AKI is much more common with trimethoprim/sulfamethoxazole therapy than previously reported. Intrinsic renal impairment rather than interstitial nephritis or competition for creatinine clearance appears responsible for the great majority of cases, and neither an effect of dose nor duration was detected in a univariate analysis. Impairment is transient if therapy is discontinued.
|
Authors | Traci Nicole Fraser, Andres A Avellaneda, Edward A Graviss, Daniel M Musher |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 67
Issue 5
Pg. 1271-7
(May 2012)
ISSN: 1460-2091 [Electronic] England |
PMID | 22351681
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Trimethoprim, Sulfamethoxazole Drug Combination
- Urea
- Creatinine
|
Topics |
- Acute Kidney Injury
(chemically induced, epidemiology)
- Aged
- Aged, 80 and over
- Anti-Bacterial Agents
(administration & dosage, adverse effects)
- Creatinine
(blood)
- Dialysis
- Female
- Humans
- Incidence
- Male
- Metabolic Clearance Rate
- Middle Aged
- Trimethoprim, Sulfamethoxazole Drug Combination
(administration & dosage, adverse effects)
- Urea
(blood)
|